United States Geographic Atrophy (GA) Market 2025: Growth Drivers, Key Players & Investment Opportunities

Global Geographic Atrophy (GA) Market reached US$ 18.5 billion in 2022 and is expected to reach US$ 35.1 billion by 2030 growing with a CAGR of 7.2% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/geographic-atrophy-market?kb

GCC Developments

✅ GCC markets (notably UAE and Saudi Arabia) are witnessing expanding ophthalmology services with increased access to GA treatments like IZERVAYTM and growth of specialized retinal care.​

✅ Healthcare modernization and medical tourism initiatives in GCC drive investment in advanced diagnostics and therapy adoption for age-related eye diseases including GA.

MENA Developments

✅ MENA botulinum toxin and aesthetic markets growing alongside retinal disease awareness, with increasing clinical trial activity and off-label use of GA treatments in regional ophthalmology centers.​

✅ Efforts underway to expand access to novel GA therapies via government reimbursement schemes and partnerships with global pharmaceutical firms.

Latest M&A

Alcon acquired LumiThera in 2025, gaining access to its Valeda® photobiomodulation device for dry AMD and early/intermediate geographic atrophy treatment, aiming to expand its GA therapeutic portfolio.​

The GA treatment sector has seen over $2 billion in M&A activity recently, driven by companies seeking innovative dry AMD therapies and complementary diagnostics.​

Increasing collaborations and acquisitions focus on gene therapies, complement inhibitors, and oral compounds targeting GA progression.

Key Players:

Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals, Inc. (US), Allegro Ophthalmics, LLC (US), Stealth BioTherapeutics (Cayman Islands), Gyroscope Therapeutics Limited (UK), Regenerative Patch Technologies, LLC (US), Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), and NGM Biopharmaceuticals Inc. (US)

New Projects

1. ONL Therapeutics initiated a Phase 2 GALAXY study in late 2025 evaluating xelafaslatide, a novel agent for GA secondary to dry AMD with remote patient monitoring elements.​

2. Boehringer Ingelheim started Phase 2 trial of an oral compound targeting GA designed to improve ease of administration and patient compliance.​

3. Clinical research expands on antigen-specific therapies aiming to halt or reverse GA progression, supported by biomarker identification and patient stratification

Growth Forecast Projection:

The Global Geographic Atrophy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

FDA Approvals

✅ Astellas' IZERVAYTM (avacincaptad pegol) received expanded FDA approval in early 2025, allowing long-term treatment of Geographic Atrophy secondary to dry AMD, after successful Phase 3 trials reducing lesion growth by up to 27%.​

✅ Pegcetacoplan (SYFOVRE) and avacincaptad pegol remain the only FDA-approved agents with demonstrated GA progression slowing.​

✅ FDA continues to require robust post-marketing clinical data focused on functional vision benefits beyond structural lesion size reduction.

Research Process:

Both primary and secondary data sources have been used in the global Geographic Atrophy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=geographic-atrophy-market?kb

Key Segmentation:

By Treatment Type: (Medication (Pegcetacoplan), AREDS2 Supplements, Implantable Miniature Telescope (IMT))

By Age Group: (Above 60 Years, Above 75 Years)

By End Users: (Hospitals, Specialty Clinics, Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Geographic Atrophy producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Geographic Atrophy revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/geographic-atrophy-market?kb

Regulatory Affairs

✅ EMA issued a negative opinion on pegcetacoplan for GA in late 2024, highlighting differences between U.S. and European regulatory stances and reflecting uncertainties on patient functional outcomes.​

✅ Regulatory focus intensifies on endpoints capturing quality of life and low luminance visual acuity alongside anatomical measures, shaping ongoing and future trial designs.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/geographic-atrophy-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.